CALHM2 and Parkinson disease: (341) observed that both conventional KO of Calhm2 and microglial KO of Calhm2 led to a significant reduction in dopaminergic neuronal loss and a decrease in microglial numbers, consequently improving locomotor performance in mice modeling PD.